Our systematic review on Covid-19, RSV, and influenza vaccines was just published in @NEJM. With federal vaccine guidance processes in flux, we felt independent evidence synthesis was crucial for the 2025-2026 respiratory virus season. 🧵 https://t.co/6Wb1pvnYku

I wrote a new piece on how much progress has been made in treating childhood leukemia. The answer is: quite a lot! Before the 1970s, fewer than 10% of children diagnosed survived 5 years after diagnosis. Now most are cured and around 85% survive that long.

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

Happy to chat with anyone interested!

The 10 most striking Kaplan-Meier curves (that I have seen) 🧵 1. Dual GLP1/GIP agonist, Tirzepatide, for prevention of type 2 diabetes in people with obesity It's easy to miss the dark blue line (15 mg group), because it never leaves the X axis:

Median age of survival for cystic fibrosis patients was 4-5 in 1954. I’m 34 in 2025. Today, some median project survival analyses say CF patients born today can expect to live to be 70+ Feels like we’re healthier now than ever before.

FDA turmoil is creating huge uncertainty for biotech... so much institutional knowledge is being lost... and upheaval is never good for productivity. One of the most challenging aspects of this uncertainty is it's not clear (at least to me) what the direction of travel will be

We welcome summer intern applications from undergrad and grad students for our CS, ML, and biochemistry efforts to work on projects such as developing ML models for drug discovery, ML kernels/infrastructure, and large-scale data management/analysis code. https://t.co/qvuZN6nkna

We’ll be hosting a recruiting talk at Hotel Bel-Ami on March 12 at 18:00 in Salon Maupassant. Join us to learn about our current research, drug discovery, machine learning, and engineering projects as well as open positions. Food and drinks will be served!

Join us to work on exciting ML projects for drug discovery, biomolecular simulation, and biophysics, e.g., generative models (incl. LLMs) to identify novel small molecules, predicting PK properties, and developing more accurate approaches for simulations. https://t.co/p2Vecdx37P

On April 10, 2025, we’ll host our Doctoral & Postdoctoral Fellowship for individuals developing machine learning and/or scientific software approaches to solve problems in drug discovery, chemistry, biology, and physics. Apply by Feb 10:

Claim: a stem-cell first This company's IVF technology matures eggs in a culture of iPSC (induced stem cell)-derived ovarian cells. A baby was born in their trial, marking "first ever human birth using using iPSC technology" company claims. couple comment in 🧵

New RCT study shows the "conventional" Novavax COVID vaccine has a similar side effect profile to the routine meningococcal vaccine, and fewer side effects than the mRNA options. Side effects are a leading cause of COVID vaccine hesitancy. This can help.

History and decision theory suggest that today's biopharma industry is short of preclinical tests (aka "assays" or "models") that accurately predict the clinical utility of drug candidates in the diseases that are still commercially interesting. 4/8

I'll have more to say about $SAVA later today, but for now... This is the best outcome for people with Alzheimer's. I wish it had come sooner. I'm sorry for the investors who will be dealing with devastating financial losses today. This entire situation got out of hand. I

Cautionary tale! Indian IST -> 62% ORR Company-sponsored US trial -> 11% ORR $CATX off 27% in the premarket.

3️⃣ Long-Term Cumulative LDL-C Exposure and ASCVD Events in Young Adults with CAC=0: Insights from the CARDIA Study https://t.co/Q6mainf2o7

CAR-T therapy shows promise for 'worst imaginable' brain tumor By ⁦@Jasonmmast⁩

Remember Golden Gate Claude? @etowah0 and I have been working on applying the same mechanistic interpretability techniques to protein language models. We found lots of features and they’re... pretty weird? 🧵

When I read news like this, it’s an example of why tech driven ethos ‘move fast, break things’ doesn’t quite work for biotech. A sense of cautious urgency is probably a better choice.